Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index; 52 of the 155 sources its claims cite were checked for support.

Mechanisms and treatment of late-life depression

Open access
Alexopoulos, George S.·2019·Translational Psychiatry

Abstract

Depression predisposes to medical illnesses and advances biological aging indicated by shorter telomere length, accelerated brain aging and advanced epigenetic aging. Medical illnesses also increase the risk of late-life depression. The reciprocal relationships of depression with aging-related and disease-related processes have generated pathogenetic hypotheses and provided treatment targets. Targeting risk factors of vascular disease in mid-life is a logical approach in prevention of vascular depression. The depression-executive dysfunction and the vascular depression syndromes have clinical presentations and neuroimaging findings consistent with frontostriatal abnormalities. Dopamine D 2/3 agonists are effective in depression of Parkinson’s disease and their efficacy needs to be assessed in these two syndromes. Computerized cognitive remediation targeting functions of the cognitive control network may improve both executive functions and depressive symptoms of late-life major depression. Significant progress has been made in neurostimulation treatments in depressed younger adults. TMS targeting deep structures responsible for mood regulation is well tolerated by older adults and its efficacy in syndromes of late-life depression needs to be studied. Efficacious psychotherapies for late-life depression exist, but are underutilized in part because of their complexity. Streamlined, stepped psychotherapies targeting behaviors assumed to result from dysfunction of brain networks implicated in late-life depression can be easy to learn and have potential for dissemination. However, their effectiveness needs further investigation. Depression increases the risk of dementing disorders. Antidepressants are rather ineffective in treating depression of demented patients, but long-term use of antidepressants may reduce the risk of dementia. However, confirmation studies are needed.

Overview

CoChat Summary

TL;DR

This review proposes that late-life depression reflects dysfunction in reward, salience, and cognitive control networks, with contributions from vascular disease, inflammation, and possibly amyloid/tau pathology. It argues that depression-executive dysfunction and vascular depression respond poorly to antidepressants and reviews novel treatments, while noting that many require confirmation.

Key findings

  • Depression was associated with 45% higher risk for stroke (95% CI 1.29–1.63) and 25% higher risk for stroke-related mortality (95% CI 1.11–1.40).
  • Approximately 30% of depressed older adults have abnormal executive test performance; depression-executive dysfunction predicts poor antidepressant response and early relapse/recurrence. In late-life major depression, antidepressant NNT was 14.4 (95% CI 8.3–50) for remission and 6.7 (95% CI 4.8–10) for response versus placebo.
  • ECT remission rates are 60–80%; right unilateral ultrabrief pulse ECT plus venlafaxine led to remission in 61.7% and response in 70%, with mean 7.3 (SD 3.1) treatments. Deep TMS produced higher remission than sham rTMS (40.0 vs. 14.8%).
  • In vascular depression, higher systolic blood pressure (147 vs. 134 mm Hg) increased odds of brain infarcts by 46%, gross infarct by 46%, and microinfarcts by 36%. Nimodipine augmentation achieved remission in 54% vs. 27% (NNT 4, 95% CI 2–12), and fewer recurrences (3.7% vs. 35.7%; NNT 3, 95% CI 2–9).

Methods

  • Narrative review of mechanisms and treatment of late-life depression, synthesizing clinical, neuroimaging, neuropathological, biomarker, and treatment literature.
  • Organizes evidence around hypotheses including depression-executive dysfunction, vascular depression, inflammation, and amyloid/tau accumulation.
  • Discusses evidence-based therapies (antidepressants, ECT, psychotherapy) and novel therapies (D2/3 agonists, computerized cognitive remediation, TMS, antihypertensives, statins, anti-inflammatory agents).

Limitations

  • Stated: most novel treatments are not clinically used because of inadequate empirical evidence, small effect size, cost, complexity of administration, and other factors; confirmation studies are needed.
  • Stated: discrepancies in amyloid/tau studies make it unclear whether and which Alzheimer’s-related neurobiological changes relate to late-life depression; some neuropathology studies failed to link vascular brain lesions with depression.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy, formal quality appraisal, or meta-analytic synthesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41398-019-0514-6

Cites

200 of 200 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Reciprocal relationship of depression and medical health
Fig. 1 Reciprocal relationship of depression and medical healthCC BY · PubMed Central
Fig. 2 Working model of late-life depression
Fig. 2 Working model of late-life depressionCC BY · PubMed Central

Verification

Claims the paper makes

43 Valid · 7 Not valid · 65 Not checked · 7 Own results and interpretations

77 more claims · 34 with their cited sources checked

Create a free account to see all 122 claims and to verify the 103 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 200 references

Research works printed but not linked: 1

  1. NAS. Standrards for Psychosocial Interventions. (NAS, Washington, D.C, 2015).

Cited by

See all 592

Metadata

Authors
Alexopoulos, G. S.
Affiliations
Cornell University (US)
Corresponding author
Alexopoulos, George S.
Venue
Translational Psychiatry
Published
2019-08-05
Volume
9
Issue
1
Pages
188-188
ISSN
2158-3188 (ISSN-L)
OpenAlex
W2964643970
Cited by
592
References
200
Citations by year
2026: 87 · 2025: 95 · 2024: 111 · 2023: 99 · 2022: 78 · 2021: 86 · 2020: 34
FWCI
6.34
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P50 MH113838, R01 MH102252)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
geriatric depression, vascular depression, telomere length, brain aging, epigenetic aging, executive dysfunction, Parkinson's disease, cognitive control network, transcranial magnetic stimulation, psychotherapy, dementia risk, antidepressants, older adults
MeSH terms
Aged, Major Depressive Disorder, Humans, Parkinson Disease, Vascular Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms and treatment of late-life depression. https://app.cochat.ai/papers/10.1038/s41398-019-0514-6
The paper
Alexopoulos, G. S. (2019). Mechanisms and treatment of late-life depression. Translational Psychiatry. https://doi.org/10.1038/s41398-019-0514-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.